{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:02:07Z","timestamp":1791241327794,"version":"4.1.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/mop.0000000000000046","type":"journal-article","created":{"date-parts":[[2013,12,9]],"date-time":"2013-12-09T09:23:13Z","timestamp":1386580993000},"page":"19-28","source":"Crossref","is-referenced-by-count":277,"title":["Hepatoblastoma state of the art"],"prefix":"10.1097","volume":"26","author":[{"given":"Piotr","family":"Czauderna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Lopez-Terrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiso","family":"Hiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"H\u00e4berle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio H.","family":"Malogolowkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka L.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-5-20210206","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/jnci\/80.20.1626","article-title":"Hepatoblastoma and familial adenomatous polyposis.","volume":"80","author":"Garber","year":"1988","journal-title":"J Natl Cancer Inst"},{"key":"R3-5-20210206","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10024-005-1154-9","article-title":"Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives.","volume":"8","author":"Cohen","year":"2005","journal-title":"Pediatr Dev Pathol"},{"key":"R4-5-20210206","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0959-8049(03)00618-X","article-title":"Familial hepatoblastoma and APC gene mutations: renewed call for molecular research.","volume":"39","author":"Thomas","year":"2003","journal-title":"Eur J Cancer"},{"key":"R5-5-20210206","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/1097-0142(19890901)64:5<1169::AID-CNCR2820640534>3.0.CO;2-I","article-title":"A case-control study of risk factors for hepatoblastoma. A report from the Childrens Cancer Study Group.","volume":"64","author":"Buckley","year":"1989","journal-title":"Cancer"},{"key":"R7-5-20210206","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/pbc.24215","article-title":"The epidemiology of hepatoblastoma.","volume":"59","author":"Spector","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R8-5-20210206","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5858\/2007-131-520-PFTEOS","article-title":"Protocol for the examination of specimens from pediatric patients with hepatoblastoma.","volume":"131","author":"Finegold","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"R9-5-20210206","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/pbc.22088","article-title":"Pretreatment prognostic factors in hepatoblastoma: a report of the Childrens Oncology Group.","volume":"53","author":"Meyers","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R10-5-20210206","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0046-8177(83)80005-7","article-title":"Primary hepatic tumors of childhood.","volume":"14","author":"Weinberg","year":"1983","journal-title":"Hum Pathol"},{"key":"R11-5-20210206","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1200\/JCO.2010.29.3837","article-title":"Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Childrens Oncology Group.","volume":"29","author":"Malogolowkin","year":"2011","journal-title":"J Clin Oncol"},{"key":"R12-5-20210206","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/pbc.24217","article-title":"Hepatoblastoma clinical research: lessons learned and future challenges.","volume":"59","author":"Perilongo","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R14-5-20210206","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/1097-0142(197003)25:3<551::AID-CNCR2820250309>3.0.CO;2-5","article-title":"Histologic classification of liver-cell carcinoma in infancy and childhood and its clinical evaluation. A study of 70 cases collected in Japan.","volume":"25","author":"Kasai","year":"1970","journal-title":"Cancer"},{"key":"R15-5-20210206","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/1097-0142(20011215)92:12<3130::AID-CNCR10115>3.0.CO;2-#","article-title":"Small cell undifferentiated histology in hepatoblastoma may be unfavorable.","volume":"92","author":"Haas","year":"2001","journal-title":"Cancer"},{"key":"R16-5-20210206","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/pbc.21834","article-title":"Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors.","volume":"52","author":"Trobaugh-Lotrario","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R17-5-20210206","first-page":"136","article-title":"Hepatoblastoma.","volume":"11","author":"Stocker","year":"1994","journal-title":"Semin Diagn Pathol"},{"key":"R18-5-20210206","first-page":"901","article-title":"Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma.","volume":"7","author":"Takayasu","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R19-5-20210206","first-page":"2864","article-title":"Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam.","volume":"60","author":"Anna","year":"2000","journal-title":"Cancer Res"},{"key":"R20-5-20210206","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/sj.bjc.6602054","article-title":"High expression of telomerase is an independent prognostic indicator of poor outcome in hepatoblastoma.","volume":"91","author":"Hiyama","year":"2004","journal-title":"Br J Cancer"},{"key":"R21-5-20210206","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccr.2008.11.002","article-title":"Hepatic stem-like phenotype and interplay of Wntbeta-catenin and Myc signaling in aggressive childhood liver cancer.","volume":"14","author":"Cairo","year":"2008","journal-title":"Cancer Cell"},{"key":"R22-5-20210206","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.neo.7900134","article-title":"Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues.","volume":"3","author":"Hiyama","year":"2001","journal-title":"Neoplasia"},{"key":"R23-5-20210206","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.onc.1205070","article-title":"Clinical utility of telomerase in cancer.","volume":"21","author":"Hiyama","year":"2002","journal-title":"Oncogene"},{"key":"R24-5-20210206","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature08137","article-title":"Telomerase modulates Wnt signalling by association with target gene chromatin.","volume":"460","author":"Park","year":"2009","journal-title":"Nature"},{"key":"R25-5-20210206","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/j.jpedsurg.2011.09.003","article-title":"Wnt signaling and telomerase activation of hepatoblastoma: correlation with chemosensitivity and surgical resectability.","volume":"46","author":"Ueda","year":"2011","journal-title":"J Pediatr Surg"},{"key":"R26-5-20210206","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.biocel.2009.07.012","article-title":"Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model.","volume":"43","author":"Armengol","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"key":"R27-5-20210206","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/cncr.10632","article-title":"Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB94.","volume":"95","author":"Fuchs","year":"2002","journal-title":"Cancer"},{"key":"R28-5-20210206","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.2005.07.145","article-title":"Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the international society of pediatric oncology liver tumor study group SIOPEL-1 study.","volume":"23","author":"Aronson","year":"2005","journal-title":"J Clin Oncol"},{"key":"R29-5-20210206","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.ejca.2011.12.011","article-title":"Prognostic stratification for children with hepatoblastoma: the SIOPEL experience.","volume":"48","author":"Maibach","year":"2012","journal-title":"Eur J Cancer"},{"key":"R32-5-20210206","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.2005.02.6013","article-title":"Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma.","volume":"24","author":"Malogolowkin","year":"2006","journal-title":"J Clin Oncol"},{"key":"R33-5-20210206","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2741\/e395","article-title":"Treatment of hepatoblastoma in German cooperative pediatric liver tumor studies.","volume":"1","author":"Haeberle","year":"2012","journal-title":"Front Biosci"},{"key":"R34-5-20210206","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2003.06.003","article-title":"Risk adapted treatment for childhood hepatoblastoma: final report of the second study of the internal society of pediatric oncology, SIOPEL 2.","volume":"40","author":"Perilongo","year":"2004","journal-title":"Eur J Cancer"},{"key":"R35-5-20210206","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJMoa0810613","article-title":"Cisplatin versus cisplatin plus doxorubicin for standard risk hepatoblastoma.","volume":"361","author":"Perilongo","year":"2009","journal-title":"N Engl J Med"},{"key":"R36-5-20210206","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.2009.22.4857","article-title":"Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.","volume":"28","author":"Zsiros","year":"2010","journal-title":"J Clin Oncol"},{"key":"R37-5-20210206","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/jpsu.2002.32886","article-title":"Outcome of hepatoblastoma treatment with JPLT-1 Protocol-1: a report from the Japanese study group for pediatric liver tumor.","volume":"37","author":"Sasaki","year":"2002","journal-title":"J Pediatr Surg"},{"key":"R38-5-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00383-010-2708-0","article-title":"Outcome of hepatoblastoma treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT.","volume":"27","author":"Hishiki","year":"2011","journal-title":"Pediatr Surg Int"},{"key":"R39-5-20210206","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1200\/JCO.2000.18.14.2665","article-title":"Randomized comparison of cisplatinvincristin5-fluorouracil and cisplatindoxorubicin for the treatment of pediatric hepatoblastoma (HB): A report from the Childrens Cancer Group and the Pediatric Oncology Group.","volume":"18","author":"Ortega","year":"2000","journal-title":"J Clin Oncol"},{"key":"R40-5-20210206","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/pbc.24220","article-title":"Surgical treatment of hepatoblastoma.","volume":"59","author":"Meyers","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R41-5-20210206","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","article-title":"Dose-dense cisplatin-based chemotherapy and surgery for children with high risk hepatoblastoma (SIOPEL 4): a prospective, single-arm, feasibility study.","volume":"14","author":"Zsiros","year":"2013","journal-title":"Lancet Oncol"},{"key":"R42-5-20210206","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2000.18.22.3819","article-title":"Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach - results of the first prospective study of the International Society of Pediatric Oncology.","volume":"18","author":"Pritchard","year":"2000","journal-title":"J Clin Oncol"},{"key":"R43-5-20210206","first-page":"791","article-title":"Dose-intensive cisplatin for hepatoblastoma: have you heard Lancet O","volume":"14","author":"Qayed","year":"2013","journal-title":"ncol"},{"key":"R44-5-20210206","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/pbc.24219","article-title":"Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies.","volume":"59","author":"Troubaugh-Lotrario","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R45-5-20210206","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ejca.2012.10.003","article-title":"Relapses in hepatoblastoma patients: clinical characteristics and outcome - experience of the International Childhood Liver Tumour Strategy Group (SIOPEL).","volume":"49","author":"Semeraro","year":"2013","journal-title":"Eur J Cancer"},{"key":"R46-5-20210206","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1200\/JCO.2006.09.7204","article-title":"Redefining the role of doxorubicin for the treatment of children with hepatoblastoma.","volume":"26","author":"Malogolowkin","year":"2008","journal-title":"J Clin Oncol"},{"key":"R47-5-20210206","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1200\/JCO.2002.07.400","article-title":"Treatment of unresectable and metastatic hepatoblastoma: a Pediatric Oncology Group phase II study.","volume":"20","author":"Katzenstein","year":"2002","journal-title":"J Clin Oncol"},{"key":"R48-5-20210206","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/pbc.22408","article-title":"Irinotecan as maintenance therapy in high-risk hepatoblastoma.","volume":"54","author":"Qayed","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R49-5-20210206","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.ejca.2012.06.023","article-title":"Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma - a phase II trial of the childhood liver tumour strategy group (SIOPEL).","volume":"48","author":"Zsiros","year":"2012","journal-title":"Eur J Cancer"},{"key":"R50-5-20210206","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1620\/tjem.184.247","article-title":"Peripheral blood stem cell transplantation for hepatoblastoma with microscopical residue: a therapeutic approach for incompletely resected tumor.","volume":"184","author":"Yoshinari","year":"1998","journal-title":"Tohoku J Exp Med"},{"key":"R51-5-20210206","first-page":"148","article-title":"Autologous peripheral blood stem-cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation: a valid therapeutic option or just too much Pediatr T","volume":"13","author":"Perilongo","year":"2009","journal-title":"ransplant"},{"key":"R52-5-20210206","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1399-3046.2008.00948.x","article-title":"Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation.","volume":"13","author":"Niwa","year":"2009","journal-title":"Pediatr Transplant"},{"key":"R53-5-20210206","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO.2000.18.6.1279","article-title":"Feasibility and toxicity of chemoembolization for children with liver tumors.","volume":"18","author":"Malogolowkin","year":"2000","journal-title":"J Clin Oncol"},{"key":"R54-5-20210206","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/pbc.20422","article-title":"Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children.","volume":"46","author":"Czauderna","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"R55-5-20210206","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jpedsurg.2007.08.030","article-title":"Surgical resection of pulmonary metastatic lesions in hepatoblastoma.","volume":"42","author":"Meyers","year":"2007","journal-title":"J Pediatr Surg"},{"key":"R56-5-20210206","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1399-3046.2006.00517.x","article-title":"Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan.","volume":"10","author":"Ijichi","year":"2006","journal-title":"Pediatr Transplant"},{"key":"R57-5-20210206","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/pbc.22544","article-title":"A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Childrens Oncology Group study.","volume":"55","author":"Beaty","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R58-5-20210206","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1054\/bjoc.1999.1179","article-title":"Altered expression of members of the IGF-axis in hepatoblastomas.","volume":"82","author":"Gray","year":"2000","journal-title":"Br J Cancer"},{"key":"R59-5-20210206","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.3748\/wjg.v12.i40.6531","article-title":"Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma.","volume":"12","author":"Tomizawa","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R60-5-20210206","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1158\/1078-0432.CCR-08-2878","article-title":"Activation of phosphatidylinositol-3-kinaseAKT signaling is essential in hepatoblastoma survival.","volume":"15","author":"Hartmann","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R61-5-20210206","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy.","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R63-5-20210206","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1517\/14712590903136696","article-title":"Emerging gene-directed antitumor strategies against human hepatoblastoma.","volume":"9","author":"Warmann","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"R64-5-20210206","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/pbc.22740","article-title":"Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.","volume":"55","author":"Lieber","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R65-5-20210206","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00262-008-0619-x","article-title":"Targets for active immunotherapy against pediatric solid tumors.","volume":"58","author":"Jacobs","year":"2009","journal-title":"Cancer Immunol Immunother"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:28:11Z","timestamp":1620962891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201402000-00005"}},"subtitle":["pathology, genetics, risk stratification, and chemotherapy"],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000046","relation":{},"ISSN":["1040-8703"],"issn-type":[{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}